Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gaucher disease: multiple lessons from a single gene disorder.

Ernest Beutler1

  • 1The Scripps Research Institute, La Jolla, CA 92037, USA. beutler@scripps.edu

Acta Paediatrica (Oslo, Norway : 1992). Supplement
|May 25, 2006
PubMed
Summary

Gaucher disease, a common lysosomal storage disorder caused by glucocerebrosidase deficiency, is increasingly treatable with enzyme and substrate reduction therapies. Lessons learned may aid other rare lysosomal storage diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Memoriam Professor Shiro Miwa.

International journal of hematology·2018
Same author

Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6.

British journal of haematology·2009
Same author

Genetic screening for low-penetrance variants in protein-coding genes.

Annual review of genomics and human genetics·2009
Same author

Regulation of hepcidin and iron-overload disease.

Annual review of pathology·2009
Same author

The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.

Blood cells, molecules & diseases·2009
Same author

Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness.

Blood·2008

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Gaucher disease is the most prevalent lysosomal storage disease.
  • It stems from a deficiency in glucocerebrosidase, leading to lipid accumulation in macrophages.
  • Specific GBA gene mutations are common in Ashkenazi Jewish and non-Jewish populations.

Purpose of the Study:

  • To review the pathophysiology of Gaucher disease.
  • To discuss current and emerging therapeutic strategies.
  • To highlight the potential application of Gaucher disease insights to other lysosomal storage diseases.

Main Methods:

  • Literature review of Gaucher disease.
  • Analysis of genetic mutations and their prevalence.
  • Overview of treatment modalities including enzyme replacement, substrate reduction, and chaperone therapy.

Related Experiment Videos

Main Results:

  • Gaucher disease is characterized by glucocerebrosidase deficiency and glucocerebroside accumulation.
  • Key GBA mutations identified in different populations.
  • Effective treatments now include enzyme replacement and substrate reduction therapies.

Conclusions:

  • Gaucher disease management has advanced significantly from symptomatic care to targeted therapies.
  • Chaperone therapy represents a potential future treatment avenue.
  • Insights from Gaucher disease research can inform the development of therapies for other lysosomal storage diseases.